212 related articles for article (PubMed ID: 36523162)
41. Medication use evaluation of programmed death-1 inhibitors in a veteran population.
Nguyen V; Huq M
J Oncol Pharm Pract; 2019 Jul; 25(5):1066-1075. PubMed ID: 29726785
[TBL] [Abstract][Full Text] [Related]
42. Nivolumab-induced hypophysitis causing secondary adrenal insufficiency after transient ACTH elevation.
Sekizaki T; Kameda H; Oba C; Yong Cho K; Nakamura A; Miyoshi H; Osawa T; Shinohara N; Atsumi T
Endocr J; 2019 Oct; 66(10):937-941. PubMed ID: 31217401
[TBL] [Abstract][Full Text] [Related]
43. Nivolumab versus pembrolizumab in previously-treated advanced non-small cell lung cancer patients: A propensity-matched real-world analysis.
Torasawa M; Yoshida T; Yagishita S; Shimoda Y; Shirasawa M; Matsumoto Y; Masuda K; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Yamamoto N; Takahashi K; Ohe Y
Lung Cancer; 2022 May; 167():49-57. PubMed ID: 35397298
[TBL] [Abstract][Full Text] [Related]
44. Predictive value of serum protein levels in patients with advanced non-small cell lung cancer treated with nivolumab.
Oyanagi J; Koh Y; Sato K; Mori K; Teraoka S; Akamatsu H; Kanai K; Hayata A; Tokudome N; Akamatsu K; Nakanishi M; Ueda H; Yamamoto N
Lung Cancer; 2019 Jun; 132():107-113. PubMed ID: 31097082
[TBL] [Abstract][Full Text] [Related]
45. Clinical characteristics and treatment efficacy of immune checkpoint inhibitors (ICIs) in patients with ICIs-induced Adrenal insufficiency.
Xiang J; Liu X; Hao Y; Zhu Y; Wu M; Lou J; Wang Y; Xu C; Xie Y; Huang J
Transl Oncol; 2023 Dec; 38():101787. PubMed ID: 37729740
[TBL] [Abstract][Full Text] [Related]
46. Nivolumab-induced Hypophysitis, Secondary Adrenal Insufficiency and Destructive Thyroiditis in a Patient with Lung Adenocarcinoma.
Mishima Y; Fukaishi T; Inase N; Isogai S
Intern Med; 2019 Mar; 58(5):693-697. PubMed ID: 30449786
[TBL] [Abstract][Full Text] [Related]
47. Risk factors for severe immune-related adverse events after first-line pembrolizumab monotherapy or combination chemotherapy for non-small-cell lung cancer.
Sumi T; Koshshino Y; Sekikawa M; Nagahisa Y; Matsuura K; Shijubou N; Kamada K; Watanabe H; Michimata H; Nagayama D; Tanaka Y; Yamada Y; Chiba H
Invest New Drugs; 2022 Dec; 40(6):1298-1305. PubMed ID: 36227514
[TBL] [Abstract][Full Text] [Related]
48. A case of Empty Sella syndrome with adrenal insufficiency masked by prednisolone after administration of immune checkpoint inhibitors.
Iwamoto Y; Tatsumi F; Ohnishi M; Katakura Y; Kimura T; Shimoda M; Nakanishi S; Mune T; Kaneto H
Medicine (Baltimore); 2024 Mar; 103(10):e37204. PubMed ID: 38457550
[TBL] [Abstract][Full Text] [Related]
49. Human leucocyte antigen DR15, a possible predictive marker for immune checkpoint inhibitor-induced secondary adrenal insufficiency.
Yano S; Ashida K; Sakamoto R; Sakaguchi C; Ogata M; Maruyama K; Sakamoto S; Ikeda M; Ohe K; Akasu S; Iwata S; Wada N; Matsuda Y; Nakanishi Y; Nomura M; Ogawa Y
Eur J Cancer; 2020 May; 130():198-203. PubMed ID: 32229416
[TBL] [Abstract][Full Text] [Related]
50. Isolated Adrenocorticotropic Hormone Deficiency Associated with Severe Hyperkalemia During Pembrolizumab Therapy in a Patient with Ureteral Cancer and an Ileal Conduit: A Case Report and Literature Review.
Hinata Y; Ohara N; Sakurai Y; Koda R; Yoneoka Y; Takada T; Hara N; Nishiyama T
Am J Case Rep; 2021 Jul; 22():e931639. PubMed ID: 34262010
[TBL] [Abstract][Full Text] [Related]
51. Association Between Early Immune-related Adverse Events and Clinical Outcomes in Patients With Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors.
Hosoya K; Fujimoto D; Morimoto T; Kumagai T; Tamiya A; Taniguchi Y; Yokoyama T; Ishida T; Hirano K; Matsumoto H; Kominami R; Tomii K; Suzuki H; Hirashima T; Uchida J; Morita M; Kanazu M; Sawa N; Makio T; Hara S; Tamiya M
Clin Lung Cancer; 2020 Jul; 21(4):e315-e328. PubMed ID: 32113737
[TBL] [Abstract][Full Text] [Related]
52. Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study.
Leighl NB; Hellmann MD; Hui R; Carcereny E; Felip E; Ahn MJ; Eder JP; Balmanoukian AS; Aggarwal C; Horn L; Patnaik A; Gubens M; Ramalingam SS; Lubiniecki GM; Zhang J; Piperdi B; Garon EB
Lancet Respir Med; 2019 Apr; 7(4):347-357. PubMed ID: 30876831
[TBL] [Abstract][Full Text] [Related]
53. Occurrence and number of immune-related adverse events are independently associated with survival in advanced non-small-cell lung cancer treated by nivolumab.
Bouhlel L; Doyen J; Chamorey E; Poudenx M; Ilie M; Gal J; Guigay J; Benzaquen J; Marquette CH; Berthet JP; Mouroux J; Schiappa R; Padovani B; Hofman P; Otto J
Bull Cancer; 2020 Sep; 107(9):946-958. PubMed ID: 32646604
[TBL] [Abstract][Full Text] [Related]
54. Non-small cell lung cancer with tumor proportion score > 90% could increase the risk of severe immune-related adverse events in first-line treatments with immune checkpoint inhibitors: A retrospective single-center study.
Akazawa Y; Yoshikawa A; Kanazu M; Yano Y; Yamaguchi T; Mori M
Thorac Cancer; 2022 Sep; 13(17):2450-2458. PubMed ID: 35820673
[TBL] [Abstract][Full Text] [Related]
55. Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition.
Naqash AR; Appah E; Yang LV; Muzaffar M; Marie MA; Mccallen JD; Macherla S; Liles D; Walker PR
J Immunother Cancer; 2019 Jul; 7(1):169. PubMed ID: 31277704
[TBL] [Abstract][Full Text] [Related]
56. Clinical difference between discontinuation and retreatment with nivolumab after immune-related adverse events in patients with lung cancer.
Mouri A; Kaira K; Yamaguchi O; Shiono A; Miura Y; Hashimoto K; Nishihara F; Murayama Y; Kobayashi K; Kagamu H
Cancer Chemother Pharmacol; 2019 Oct; 84(4):873-880. PubMed ID: 31444618
[TBL] [Abstract][Full Text] [Related]
57. Frequency and imaging features of abdominal immune-related adverse events in metastatic lung cancer patients treated with PD-1 inhibitor.
Alessandrino F; Sahu S; Nishino M; Adeni AE; Tirumani SH; Shinagare AB; Awad MM
Abdom Radiol (NY); 2019 May; 44(5):1917-1927. PubMed ID: 30790009
[TBL] [Abstract][Full Text] [Related]
58. Immunotherapy as second-line treatment and beyond for non-small cell lung cancer in a single center of China: Outcomes, toxicities, and clinical predictive factors from a real-world retrospective analysis.
Chen M; Li Q; Xu Y; Zhao J; Zhang L; Wei L; Zhong W; Wang M
Thorac Cancer; 2020 Jul; 11(7):1955-1962. PubMed ID: 32468726
[TBL] [Abstract][Full Text] [Related]
59. Corticotropic insufficiency in a monocentric prospective cohort of patients with lung cancer treated with nivolumab: Prevalence and etiology.
Ducloux R; Tavernier JY; Wojewoda P; Toullet F; Romanet S; Averous V
Ann Endocrinol (Paris); 2021 Feb; 82(1):8-14. PubMed ID: 33290748
[TBL] [Abstract][Full Text] [Related]
60. Immune checkpoint inhibitors and adrenal insufficiency: a large-sample case series study.
Cui K; Wang Z; Zhang Q; Zhang X
Ann Transl Med; 2022 Mar; 10(5):251. PubMed ID: 35402601
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
